BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29848756)

  • 1. Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles.
    Frutoso M; Morisseau S; Tamzalit F; Quéméner A; Meghnem D; Leray I; Jacques Y; Mortier E
    J Immunol; 2018 Jul; 201(2):493-506. PubMed ID: 29848756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
    Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
    J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
    Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
    J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells.
    Davies E; Reid S; Medina MF; Lichty B; Ashkar AA
    J Leukoc Biol; 2010 Sep; 88(3):529-36. PubMed ID: 20538758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
    Rowley J; Monie A; Hung CF; Wu TC
    J Immunol; 2008 Dec; 181(12):8237-47. PubMed ID: 19050240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity.
    Kasaian MT; Whitters MJ; Carter LL; Lowe LD; Jussif JM; Deng B; Johnson KA; Witek JS; Senices M; Konz RF; Wurster AL; Donaldson DD; Collins M; Young DA; Grusby MJ
    Immunity; 2002 Apr; 16(4):559-69. PubMed ID: 11970879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice.
    Gao K; Li X; Zhang L; Bai L; Dong W; Gao K; Shi G; Xia X; Wu L; Zhang L
    Cancer Lett; 2013 Jul; 335(2):463-71. PubMed ID: 23499895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
    Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
    J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells.
    Combe CL; Curiel TJ; Moretto MM; Khan IA
    Infect Immun; 2005 Aug; 73(8):4913-21. PubMed ID: 16041005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.
    Elpek KG; Rubinstein MP; Bellemare-Pelletier A; Goldrath AW; Turley SJ
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21647-52. PubMed ID: 21098276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
    Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
    J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2 responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2Rbeta transgenic mice.
    Gesbert F; Moreau JL; Thèze J
    Int Immunol; 2005 Aug; 17(8):1093-102. PubMed ID: 16037071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
    Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
    Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
    Guo Y; Luan L; Rabacal W; Bohannon JK; Fensterheim BA; Hernandez A; Sherwood ER
    J Immunol; 2015 Sep; 195(5):2353-64. PubMed ID: 26216888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii.
    Lieberman LA; Villegas EN; Hunter CA
    Infect Immun; 2004 Nov; 72(11):6729-32. PubMed ID: 15501812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.